- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tofacitinib tied to reduced incidence of ILD among Rheumatoid arthritis patients
An Original Investigation in Rheumatology published in JAMA Network Open has found a reduced risk of developing interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients treated with tofacitinib. The risk was reduced by 69%, according to them.
Matthew C. Baker said that future prospective studies with tofacitinib to prevent RA-ILD should be considered.
Insufficient data and research are available on the risk of usage of biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) on developing interstitial lung disease (ILD) in RA patients.
Considering this background, researchers determined the risk of developing ILD in patients with RA undergoing treatment with different b/tsDMARDs in their respective cohort studies. They calculated Crude incidence rates (IRs) for developing ILD and compared ILD risk in adults with RA, one year or more of continuous enrollment, treatment with a b/tsDMARD of interest, and without preexisting ILD.
They used data from Optum Clinformatics Data Mart (December 2003-December 2019). The exposures in the study were the new administration of adalimumab, abatacept, rituximab, tocilizumab, and tofacitinib.
The results of the research study are:
- Twenty-eight thousand five hundred fifty-nine patients with RA mean age of 55.6 years were included.
- The number of patients treated with adalimumab, abatacept, rituximab, tocilizumab, and tofacitinib were 22 158, 13 326, 5676, 5444, 2548 patients and 1565, respectively.
- Crude IRs per 1000 person-years for ILD for adalimumab, abatacept, rituximab, tocilizumab, and tofacitinib were 3.43, 4.46, 6.15, 5.05, and 1.47, respectively.
- Patients treated with tofacitinib had a lower risk of ILD with aHR of 0.31.4
- Patients treated with tofacitinib had a 68% reduced risk of ILD than adalimumab with aHR 0.32.
- The risk was reduced by 69% of ILD in patients treated with tofacitinib than those treated with adalimumab.
Concluding further, they said among RA patients, those treated with tofacitinib had the lowest incidence of ILD. More research is required to understand how tofacitinib prevents ILD in patients with RA.
They also mentioned words of caution, saying results should be interpreted with caution due to the relatively small sample size of the tofacitinib group.
Further reading:
Baker MC, Liu Y, Lu R, Lin J, Melehani J, Robinson WH. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs. JAMA Netw Open. 2023;6(3):e233640. doi:10.1001/jamanetworkopen.2023.3640
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751